AAAAAA
Results: 1-25/1095
Authors:
Maurel, J
Zorrilla, M
Puertolas, T
Anton, A
Herrero, A
Artal, A
Alonso, V
Martinez-Trufero, J
Puertas, MD
Citation: J. Maurel et al., Phase I trial of weekly gemcitabine at 3-h infusion in refractory, heavilypretreated advanced solid tumors, ANTI-CANC D, 12(9), 2001, pp. 713-717
Authors:
Wilailak, S
Linasmita, V
Srisupundit, S
Citation: S. Wilailak et al., Phase II study of high-dose megestrol acetate in platinum-refractory epithelial ovarian cancer, ANTI-CANC D, 12(9), 2001, pp. 719-724
Authors:
Heider, A
Niederle, N
Citation: A. Heider et N. Niederle, Efficacy and toxicity of bendamustine in patients with relapsed low-grade non-Hodgkin's lymphomas, ANTI-CANC D, 12(9), 2001, pp. 725-729
Authors:
Suzuma, T
Sakurai, T
Yoshimura, G
Umemura, T
Tamaki, T
Yoshimasu, T
Naito, Y
Citation: T. Suzuma et al., Pamidronate-induced remission of pain associated with hypertrophic pulmonary osteoarthropathy in chemoendocrine therapy-refractory inoperable metastatic breast carcinoma, ANTI-CANC D, 12(9), 2001, pp. 731-734
Authors:
Mohammad, RM
Adsay, NV
Philip, PA
Pettit, GR
Vaitkevicius, VK
Sarkar, FH
Citation: Rm. Mohammad et al., Bryostatin 1 induces differentiation and potentiates the antitumor effect of Auristatin PE in a human pancreatic tumor (PANC-1) xenograft model, ANTI-CANC D, 12(9), 2001, pp. 735-740
Authors:
Guichard, S
Arnould, S
Hennebelle, I
Bugat, R
Canal, P
Citation: S. Guichard et al., Combination of oxaliplatin and irinotecan on human colon cancer cell lines: activity in vitro and in vivo, ANTI-CANC D, 12(9), 2001, pp. 741-751
Authors:
Darling, JL
Thomas, DGT
Citation: Jl. Darling et Dgt. Thomas, Response of short-term cultures derived from human malignant glioma to aziridinylbenzoquinone, etoposide and doxorubicin: an in vitro phase II trial, ANTI-CANC D, 12(9), 2001, pp. 753-760
Authors:
Chatzistamou, I
Schally, AV
Varga, JL
Groot, K
Busto, R
Armatis, P
Halmos, G
Citation: I. Chatzistamou et al., Inhibition of growth and metastases of MDA-MB-435 human estrogen-independent breast cancers by an antagonist of growth hormone-releasing hormone, ANTI-CANC D, 12(9), 2001, pp. 761-768
Authors:
Uchiyama-Kokubu, N
Watanabe, T
Citation: N. Uchiyama-kokubu et T. Watanabe, Establishment and characterization of adriamycin-resistant human colorectal adenocarcinoma HCT-15 cell lines with multidrug resistance, ANTI-CANC D, 12(9), 2001, pp. 769-779
Authors:
Huang, YN
Xu, YY
Yamagishi, H
Hagiwara, A
Citation: Yn. Huang et al., Tumor cytotoxicity of peritoneal macrophages induced by OK-432, ANTI-CANC D, 12(9), 2001, pp. 781-785
Citation: Abstracts of the 1st Symposium of the International Society for Chemosensitivity Testing in Oncology - ISCO-1 - September 14-15, 2001 - Schlossberg Hotel Homburg/Saar, Germany, ANTI-CANC D, 12(8), 2001, pp. A3-A16
Authors:
Johnston, PG
Kaye, S
Citation: Pg. Johnston et S. Kaye, Capecitabine: a novel agent for the treatment of solid tumors, ANTI-CANC D, 12(8), 2001, pp. 639-646
Authors:
Underhill, CR
Parnis, FX
Highley, MS
Ahern, J
Harper, PG
Hansen, H
Lund, B
Dombernowsky, P
Hirsch, F
Hansen, M
Carmichael, J
Williams, C
Citation: Cr. Underhill et al., Multicenter phase II study of gemcitabine in previously untreated patientswith advanced epithelial ovarian cancer, ANTI-CANC D, 12(8), 2001, pp. 647-652
Authors:
Sparidans, RW
Rosing, H
Hillebrand, MJX
Lopez-Lazaro, L
Jimeno, JM
Manzanares, I
van Kesteren, C
Cvitkovic, E
van Oosterom, AT
Schellens, JHM
Beijnen, JH
Citation: Rw. Sparidans et al., Search for metabolites of ecteinascidin 743, a novel, marine-derived, anti-cancer agent, in man, ANTI-CANC D, 12(8), 2001, pp. 653-666
Authors:
Schellens, JHM
Planting, AST
Ma, J
Maliepaard, M
de Vos, A
Dennert, MD
Verweij, J
Citation: Jhm. Schellens et al., Adaptive intrapatient dose escalation of cisplatin in patients with advanced head and neck cancer, ANTI-CANC D, 12(8), 2001, pp. 667-675
Authors:
Tomita, N
Kanamori, H
Fujita, H
Maruta, A
Naitoh, A
Nakamura, S
Ota, Y
Nozue, N
Kihara, M
Ishigatsubo, Y
Citation: N. Tomita et al., Granulomatous tubulointerstitial nephritis induced by all-trans retinoic acid, ANTI-CANC D, 12(8), 2001, pp. 677-680
Authors:
Tanaka, M
Kanamori, H
Yamaji, S
Fujimaki, K
Tomita, N
Fujisawa, S
Ishigatsubo, Y
Citation: M. Tanaka et al., Therapy-related CD7(+) acute myeloid leukemia with trisomy 8 following acute monocytic leukemia, ANTI-CANC D, 12(8), 2001, pp. 681-682
Authors:
Gieseg, MA
de Bock, C
Ferguson, LR
Denny, WA
Citation: Ma. Gieseg et al., Evidence for epidermal growth factor receptor-enhanced chemosensitivity incombinations of cisplatin and the new irreversible tyrosine kinase inhibitor CI-1033, ANTI-CANC D, 12(8), 2001, pp. 683-690
Authors:
Takeda, Y
Yoshizaki, I
Nonaka, Y
Yanagie, H
Matsuzawa, A
Eriguchi, M
Citation: Y. Takeda et al., Docetaxel alone or orally combined with 5-fluorouracil and its derivatives: effects on mouse mammary tumor cell line MM2 in vitro and in vivo, ANTI-CANC D, 12(8), 2001, pp. 691-698
Authors:
Martinsson, P
Liminga, G
Nygren, P
Larsson, R
Citation: P. Martinsson et al., Characteristics of etoposide-induced apoptotic cell death in the U-937 human lymphoma cell line, ANTI-CANC D, 12(8), 2001, pp. 699-705
Authors:
Tashiro, K
Asakura, T
Fujiwara, C
Ohkawa, K
Ishibashi, Y
Citation: K. Tashiro et al., Glutathione-S-transferase-pi expression regulates sensitivity to glutathione-doxorubicin conjugate, ANTI-CANC D, 12(8), 2001, pp. 707-712
Authors:
Bell, R
Citation: R. Bell, Duration of therapy in metastatic breast cancer: management using Herceptin (R), ANTI-CANC D, 12(7), 2001, pp. 561-568
Authors:
Parr, AL
Myers, TG
Holbeck, SL
Loh, YLJ
Allegra, CJ
Citation: Al. Parr et al., Thymidylate synthase as a molecular target for drug discovery using the National Cancer Institute's Anticancer Drug Screen, ANTI-CANC D, 12(7), 2001, pp. 569-574
Authors:
Sparidans, RW
Stokvis, E
Jimeno, JM
Lopez-Lazaro, L
Schellens, JHM
Beijnen, JH
Citation: Rw. Sparidans et al., Chemical and enzymatic stability of a cyclic depsipeptide, the novel, marine-derived, anti-cancer agent kahalalide F, ANTI-CANC D, 12(7), 2001, pp. 575-582
Authors:
Schellens, JHM
Dombernowsky, P
Cassidy, J
Epelbaum, R
Dirix, L
Cox, EH
Wanders, J
Calabresi, F
Paridaens, R
Monfardini, S
Wolff, J
Loos, WJ
Verweij, J
Pavlidis, N
Hanauske, AR
Citation: Jhm. Schellens et al., Population pharmacokinetics and dynamics in phase II studies of the novel bioreductive alkylating cytotoxic indoloquinone EO9, ANTI-CANC D, 12(7), 2001, pp. 583-590